Sanofi (NASDAQ:SNY – Get Free Report) saw unusually large options trading on Thursday. Traders purchased 6,242 call options on the stock. This is an increase of approximately 276% compared to the average daily volume of 1,658 call options.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Rise Advisors LLC boosted its holdings in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. purchased a new position in Sanofi in the fourth quarter valued at $27,000. Venturi Wealth Management LLC boosted its holdings in Sanofi by 163.5% in the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after purchasing an additional 332 shares during the period. Frazier Financial Advisors LLC purchased a new position in Sanofi in the fourth quarter valued at $28,000. Finally, Register Financial Advisors LLC purchased a new stake in Sanofi during the 1st quarter worth about $29,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi Trading Up 0.4 %
SNY opened at $51.43 on Friday. Sanofi has a 52 week low of $42.63 and a 52 week high of $55.72. The business has a fifty day simple moving average of $48.84 and a 200-day simple moving average of $48.64. The firm has a market cap of $130.26 billion, a P/E ratio of 25.73, a P/E/G ratio of 1.58 and a beta of 0.59. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Articles
- Five stocks we like better than Sanofi
- Earnings Per Share Calculator: How to Calculate EPS
- Consumer Staple Stock’s Q2 Earnings: Key Surprises and Challenges
- What Investors Need to Know About Upcoming IPOs
- 6 Best Index Mutual Funds to Invest In
- Comparing and Trading High PE Ratio Stocks
- Falling Inflation Sparks Optimism for These 3 Home Builder Stocks
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.